Department of Anesthesia and Critical Care, The University of Chicago, Chicago, Illinois, United States.
Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, United States.
Invest Ophthalmol Vis Sci. 2014 Apr 3;55(6):3785-96. doi: 10.1167/iovs.13-11683.
Delayed treatment after ischemia is often unsatisfactory. We hypothesized that injection of bone marrow stem cell (BMSC) conditioned medium after ischemia could rescue ischemic retina, and in this study we characterized the functional and histological outcomes and mechanisms of this neuroprotection.
Retinal ischemia was produced in adult Wistar rats by increasing intraocular pressure for 55 minutes. Conditioned medium (CM) from rat BMSCs or unconditioned medium (uCM) was injected into the vitreous 24 hours after the end of ischemia. Recovery was assessed 7 days after ischemia using electroretinography, at which time we euthanized the animals and then prepared 4-μm-thick paraffin-embedded retinal sections. TUNEL and Western blot were used to identify apoptotic cells and apoptosis-related gene expression 24 hours after injections; that is, 48 hours after ischemia. Protein content in CM versus uCM was studied using tandem mass spectrometry, and bioinformatics methods were used to model protein interactions.
Intravitreal injection of CM 24 hours after ischemia significantly improved retinal function and attenuated cell loss in the retinal ganglion cell layer. CM attenuated postischemic apoptosis and apoptosis-related gene expression. By spectral counting, 19 proteins that met stringent identification criteria were increased in the CM compared to uCM; the majority were extracellular matrix proteins that mapped into an interactional network together with other proteins involved in cell growth and adhesion.
By restoring retinal function, attenuating apoptosis, and preventing retinal cell loss after ischemia, CM is a robust means of delayed postischemic intervention. We identified some potential candidate proteins for this effect.
缺血后治疗的延迟往往并不理想。我们假设,在缺血后注射骨髓间充质干细胞(BMSC)条件培养基可以挽救缺血性视网膜,在这项研究中,我们对这种神经保护的功能和组织学结果及其机制进行了描述。
通过将眼内压升高 55 分钟,在成年 Wistar 大鼠中产生视网膜缺血。在缺血结束后 24 小时,将大鼠 BMSC 的条件培养基(CM)或未处理的培养基(uCM)注入玻璃体腔。在缺血后 7 天,通过视网膜电图评估恢复情况,此时处死动物,然后制备 4-μm 厚的石蜡包埋视网膜切片。TUNEL 和 Western blot 用于在注射后 24 小时(即缺血后 48 小时)识别凋亡细胞和与凋亡相关的基因表达。
缺血后 24 小时玻璃体腔内注射 CM 可显著改善视网膜功能并减轻节细胞层的细胞丢失。CM 减轻了缺血后的凋亡和与凋亡相关的基因表达。通过串联质谱分析,与 uCM 相比,CM 中增加了 19 种符合严格鉴定标准的蛋白质;大多数是细胞外基质蛋白,与其他参与细胞生长和黏附的蛋白质一起映射到一个相互作用网络中。
通过恢复视网膜功能、减轻凋亡和防止缺血后视网膜细胞丢失,CM 是一种延迟性缺血后干预的有力手段。我们确定了一些潜在的候选蛋白,以实现这种效果。